Login Register Cart 0
Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

他汀类药物，痴呆患者的死亡风险和缺血性卒中：基于注册中心的观察性队列研究

卷 17, 期 10, 2020

页: [881 - 892] 页: 12

弟呕挨: 10.2174/1567205017666201215130254

open access plus

摘要

背景：痴呆患者的生存率是可变的。他汀类药物是预防心血管疾病的基石。但是，他汀类药物对痴呆患者的死亡率和中风风险的影响尚不清楚。 目的：本研究旨在分析他汀类药物的使用与诊断为痴呆症的全因死亡和首次缺血性中风的风险之间的关系。 方法：进行了一项纵向队列研究，共纳入48771名瑞典瑞典登记患者。使用倾向评分匹配的柔性参数或Cox危险生存模型检查了痴呆诊断前一年他汀类药物的事件使用，全因死亡率和首次缺血性卒中之间的关联，并显示了危险比和相应的95％置信区间。 结果：倾向得分匹配后，使用他汀类药物的患者（n = 1412）的全因死亡（HR 0.82，95％CI 0.74-0.91）和缺血性中风（HR 0.62，95％CI 0.43-0.89）的风险较低。与匹配的非用户相比（n = 4482）。在分层分析中，在患有老年痴呆症和血管性痴呆的男性，75岁以上的患者中观察到他汀类药物的使用与生存之间的保护性关联。此外，我们观察到他汀类药物的使用与男性，75岁以上且患有混合性痴呆的患者的首次缺血性中风风险之间存在保护性关联。他汀类药物的累积剂量与死亡率之间存在分级关联。 结论：他汀类药物的使用可能对痴呆患者的生存和缺血性卒中风险具有剂量依赖性。

关键词: 他汀类药物，HMG-CoA还原酶抑制剂，痴呆症，阿尔茨海默氏病，中风，死亡，死亡率。

« Previous Next »
[1]
Koller D, Kaduszkiewicz H, van den Bussche H, et al. Survival in patients with incident dementia compared with a control group: A five-year follow-up. Int Psychogeriatr 2012; 24(9): 1522-30.
[http://dx.doi.org/10.1017/S1041610212000361] [PMID: 22458976]
[2]
Garcia-Ptacek S, Farahmand B, Kåreholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: A cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis 2014; 41(2): 467-77.
[http://dx.doi.org/10.3233/JAD-131856] [PMID: 24625796]
[3]
García-Ptacek S, Kåreholt I, Farahmand B, Cuadrado ML, Religa D, Eriksdotter M. Body-mass index and mortality in incident dementia: A cohort study on 11,398 patients from SveDem, the Swedish Dementia Registry. J Am Med Dir Assoc 2014; 15(6): 447.e1-7.
[http://dx.doi.org/10.1016/j.jamda.2014.03.001 ] [PMID: 24721339]
[4]
Fiest KM, Jetté N, Roberts JI, et al. The prevalence and incidence of dementia: A systematic review and meta-analysis. Can J Neurol Sci 2016; 43(S1)(Suppl. 1): S3-S50.
[http://dx.doi.org/10.1017/cjn.2016.18] [PMID: 27307127]
[5]
Czuba E, Steliga A, Lietzau G, Kowiański P. Cholesterol as a modifying agent of the neurovascular unit structure and function under physiological and pathological conditions. Metab Brain Dis 2017; 32(4): 935-48.
[http://dx.doi.org/10.1007/s11011-017-0015-3] [PMID: 28432486]
[6]
Petek B, Villa-Lopez M, Loera-Valencia R, et al. Connecting the brain cholesterol and renin-angiotensin systems: Potential role of statins and RAS-modifying medications in dementia. J Intern Med 2018; 284(6): 620-42.
[http://dx.doi.org/10.1111/joim.12838] [PMID: 30264910]
[7]
Ismail MAM, Mateos L, Maioli S, et al. 27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation. J Exp Med 2017; 214(3): 699-717.
[http://dx.doi.org/10.1084/jem.20160534] [PMID: 28213512]
[8]
Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease - epidemiological evidence. Acta Neurol Scand Suppl 2006; 185(Suppl. 185): 50-7.
[http://dx.doi.org/10.1111/j.1600-0404.2006.00685.x] [PMID: 16866911]
[9]
Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350(9085): 1119-23.
[http://dx.doi.org/10.1016/S0140-6736(97)04430-9] [PMID: 9343498]
[10]
Ahmadi SF, Streja E, Zahmatkesh G, et al. Reverse epidemiology of traditional cardiovascular risk factors in the geriatric population. J Am Med Dir Assoc 2015; 16(11): 933-9.
[http://dx.doi.org/10.1016/j.jamda.2015.07.014] [PMID: 26363864]
[11]
Strandberg TE. Role of statin therapy in primary prevention of cardiovascular disease in elderly patients. Curr Atheroscler Rep 2019; 21(8): 28.
[http://dx.doi.org/10.1007/s11883-019-0793-7] [PMID: 31111235]
[12]
Koistinaho M, Koistinaho J. Interactions between Alzheimer’s disease and cerebral ischemia--focus on inflammation. Brain Res Brain Res Rev 2005; 48(2): 240-50.
[http://dx.doi.org/10.1016/j.brainresrev.2004.12.014] [PMID: 15850663]
[13]
Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. J Alzheimers Dis 2018; 65(2): 589-96.
[http://dx.doi.org/10.3233/JAD-180353] [PMID: 30056424]
[14]
de la Torre JC. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002; 33(4): 1152-62.
[http://dx.doi.org/10.1161/01.STR.0000014421.15948.67] [PMID: 11935076]
[15]
Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011; 23(2): 307-18.
[http://dx.doi.org/10.3233/JAD-2010-101179] [PMID: 21098985]
[16]
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial ischemia reduction with aggressive cholesterol lowering (miracl) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285(13): 1711-8.
[http://dx.doi.org/10.1001/jama.285.13.1711] [PMID: 11277825]
[17]
Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360(9346): 1623-30.
[http://dx.doi.org/10.1016/S0140-6736(02)11600-X] [PMID: 12457784]
[18]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
[PMID: 7968073]
[19]
Tonkin A, Alyward P, Colquhoun D, et al. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-57.
[http://dx.doi.org/10.1056/NEJM199811053391902] [PMID: 9841303]
[20]
Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
[http://dx.doi.org/10.1016/S0140-6736(02)09327-3] [PMID: 12114036]
[21]
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Obstet Gynecol Surv 2009; 64(3): 168-70.
[http://dx.doi.org/10.1097/01.ogx.0000344393.60303.0a]
[22]
Nakamura H, Arakawa K, Itakura H, et al. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368(9542): 1155-63.
[http://dx.doi.org/10.1016/S0140-6736(06)69472-5] [PMID: 17011942]
[23]
Yusuf S, Bosch J, Dagenais G, et al. HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374(21): 2021-31.
[http://dx.doi.org/10.1056/NEJMoa1600176] [PMID: 27040132]
[24]
Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.
[http://dx.doi.org/10.1016/S0140-6736(05)67394-1 ] [PMID: 16214597]
[25]
Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 2017(1)CD004816
[http://dx.doi.org/10.1002/14651858.CD004816.pub5] [PMID: 23440795]
[26]
Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51(1): 37-45.
[http://dx.doi.org/10.1016/j.jacc.2007.06.063] [PMID: 18174034]
[27]
Schwartz JB. Primary prevention: Do the very elderly require a different approach? Trends Cardiovasc Med 2015; 25(3): 228-39.
[http://dx.doi.org/10.1016/j.tcm.2014.10.010] [PMID: 25560975]
[28]
Amarenco P, Benavente O, Goldstein LB, et al. Stroke prevention by aggressive reduction in cholesterol levels investigators. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40(4): 1405-9.
[http://dx.doi.org/10.1161/STROKEAHA.108.534107] [PMID: 19228842]
[29]
Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121(1): 143-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.874834] [PMID: 20026779]
[30]
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019; 73(24): e285-350.
[http://dx.doi.org/10.1016/j.jacc.2018.11.003] [PMID: 30423393]
[31]
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation. G Ital Cardiol (Rome) 2017; 18(7): 547-612.
[PMID: 28714997]
[32]
Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016; 32(11): 1263-82.
[http://dx.doi.org/10.1016/j.cjca.2016.07.510] [PMID: 27712954]
[33]
NICE. Lipid modification: NICE guideline (CG181). Natl Inst Heal Clin Excell 2014.
[34]
Feldman HH, Doody RS, Kivipelto M, et al. LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74(12): 956-64.
[http://dx.doi.org/10.1212/WNL.0b013e3181d6476a] [PMID: 20200346]
[35]
Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77(6): 556-63.
[http://dx.doi.org/10.1212/WNL.0b013e318228bf11] [PMID: 21795660]
[36]
Trompet S, van Vliet P, de Craen AJM, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257(1): 85-90.
[http://dx.doi.org/10.1007/s00415-009-5271-7] [PMID: 19653027]
[37]
Jamolowicz AI, Chen HY, Panegyres PK. Statins and memory loss: An Australian experience. Australas Med J 2015; 8(3): 73-9.
[http://dx.doi.org/10.4066/AMJ.2015.2014] [PMID: 25870656]
[38]
Richardson K, Schoen M, French B, et al. Statins and cognitive function: A systematic review. Ann Intern Med 2013; 159(10): 688-97.
[http://dx.doi.org/10.7326/0003-4819-159-10-201311190-00007] [PMID: 24247674]
[39]
Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R. Statin use among older Finns stratified according to cardiovascular risk. Eur J Clin Pharmacol 2013; 69(2): 261-7.
[http://dx.doi.org/10.1007/s00228-012-1328-0] [PMID: 22706622]
[40]
Sundvall H, Fastbom J, Wallerstedt SM, Vitols S. Use of statins in the elderly according to age and indication-a cross-sectional population-based register study. Eur J Clin Pharmacol 2019; 75(7): 959-67.
[http://dx.doi.org/10.1007/s00228-019-02645-w ] [PMID: 30826850]
[41]
O’Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: A cohort study using The Health Improvement Network primary care data. Clin Epidemiol 2016; 8: 123-32.
[http://dx.doi.org/10.2147/CLEP.S104258] [PMID: 27313477]
[42]
Morgan TK, Williamson M, Pirotta M, Stewart K, Myers SP, Barnes J. A national census of medicines use: A 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012; 196(1): 50-3.
[http://dx.doi.org/10.5694/mja11.10698] [PMID: 22256935]
[43]
Religa D, Fereshtehnejad SM, Cermakova P, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS One 2015; 10(2)e0116538
[http://dx.doi.org/10.1371/journal.pone.0116538] [PMID: 25695768]
[44]
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
[http://dx.doi.org/10.1186/1471-2458-11-450] [PMID: 21658213]
[45]
Asplund K, Hulter Åsberg K, Norrving B, Stegmayr B, Terént A, Wester PO. Riks-Stroke Collaboration. Riks-stroke - a Swedish national quality register for stroke care. Cerebrovasc Dis 2003; 15(Suppl. 1): 5-7.
[http://dx.doi.org/10.1159/000068203] [PMID: 12649604]
[46]
Defined Daily Dose. Available from: https://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/ en/2020
[47]
Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017; 36(27): 4391-400.
[http://dx.doi.org/10.1002/sim.7501] [PMID: 28913837]
[48]
Borgquist S, Broberg P, Tojjar J, Olsson H. Statin use and breast cancer survival - a Swedish nationwide study. BMC Cancer 2019; 19(1): 54.
[http://dx.doi.org/10.1186/s12885-018-5263-z] [PMID: 30634941]
[49]
Armitage J, Baigent C, Barnes E, et al. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170): 407-15.
[http://dx.doi.org/10.1016/S0140-6736(18)31942-1] [PMID: 30712900]
[50]
Hawley CE, Roefaro J, Forman DE, Orkaby AR. Statins for primary prevention in those aged 70 years and older: A critical review of recent cholesterol guidelines. Drugs Aging 2019; 36(8): 687-99.
[http://dx.doi.org/10.1007/s40266-019-00673-w] [PMID: 31049807]
[51]
Haaksma ML, Rizzuto D, Ramakers IHGB, et al. The impact of frailty and comorbidity on institutionalization and mortality in persons with dementia: A prospective cohort study. J Am Med Dir Assoc 2019; 20(2): 165-170.e2.
[http://dx.doi.org/10.1016/j.jamda.2018.06.020] [PMID: 30145169]
[52]
Ramos R, Comas-Cufí M, Martí-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study. BMJ 2018; 362: k3359.
[http://dx.doi.org/10.1136/bmj.k3359] [PMID: 30185425]
[53]
Orkaby AR, Gaziano JM, Djousse L, Driver JA. statins for primary prevention of cardiovascular events and mortality in older men. J Am Geriatr Soc 2017; 65(11): 2362-8.
[http://dx.doi.org/10.1111/jgs.14993] [PMID: 28892121]
[54]
Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A. Real-life benefits of statins for cardiovascular prevention in elderly subjects: A population-based cohort study. Am J Med 2019; 132(6): 740-748.e7.
[http://dx.doi.org/10.1016/j.amjmed.2018.12.032] [PMID: 30660573]
[55]
Jun JE, Cho IJ, Han K, et al. Statins for primary prevention in adults aged 75 years and older: A nationwide population-based case-control study. Atherosclerosis 2019; 283: 28-34.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.01.030] [PMID: 30772771]
[56]
Kim K, Lee CJ, Shim CY, et al. Statin and clinical outcomes of primary prevention in individuals aged >75 years: The SCOPE-75 study. Atherosclerosis 2019; 284: 31-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.02.026] [PMID: 30870705]
[57]
Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: Population based cohort study. BMJ 2015; 350: h2335.
[http://dx.doi.org/10.1136/bmj.h2335] [PMID: 25989805]
[58]
Jacobs JM, Cohen A, Ein-Mor E, Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. J Am Med Dir Assoc 2013; 14(12): 883-8.
[http://dx.doi.org/10.1016/j.jamda.2013.08.012] [PMID: 24094647]
[59]
Gnjidic D, Le Couteur DG, Blyth FM, et al. Statin use and clinical outcomes in older men: A prospective population-based study. BMJ Open 2013; 3(3)e002333
[http://dx.doi.org/10.1136/bmjopen-2012-002333] [PMID: 23474793]
[60]
Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis. J Am Coll Cardiol 2013; 62(22): 2090-9.
[http://dx.doi.org/10.1016/j.jacc.2013.07.069] [PMID: 23954343]
[61]
Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994; 14(7): 1098-104.
[http://dx.doi.org/10.1161/01.ATV.14.7.1098] [PMID: 8018665]
[62]
Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001; 187(1-2): 81-9.
[http://dx.doi.org/10.1016/S0022-510X(01)00529-9] [PMID: 11440749]
[63]
Vaughan CJ. Prevention of stroke and dementia with statins: Effects beyond lipid lowering. Am J Cardiol 2003; 91(4A): 23B-9B.
[http://dx.doi.org/10.1016/S0002-9149(02)03270-8] [PMID: 12615295]
[64]
Wassmann S, Laufs U, Bäumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37(6): 1450-7.
[http://dx.doi.org/10.1161/01.HYP.37.6.1450 ] [PMID: 11408394]
[65]
Zhao J, Zhang X, Dong L, Wen Y, Cui L. The many roles of statins in ischemic stroke. Curr Neuropharmacol 2014; 12(6): 564-74.
[http://dx.doi.org/10.2174/1570159X1266614092321092] [PMID: 25977681]
[66]
Olivieri F, Mazzanti I, Abbatecola AM, et al. Telomere/Telomerase system: A new target of statins pleiotropic effect? Curr Vasc Pharmacol 2012; 10(2): 216-24.
[http://dx.doi.org/10.2174/157016112799305076] [PMID: 22022767]
[67]
Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: Lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012; 175(4): 250-62.
[http://dx.doi.org/10.1093/aje/kwr301 ] [PMID: 22223710]
[68]
Enache D, Fereshtehnejad SM, Kåreholt I, et al. Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. Acta Psychiatr Scand 2016; 134(5): 430-40.
[http://dx.doi.org/10.1111/acps.12630] [PMID: 27586958]
[69]
Kuss O, Blettner M, Börgermann J. Propensity score: An alternative method of analyzing treatment effects. Dtsch Arztebl Int 2016; 113(35-36): 597-603.
[http://dx.doi.org/10.3238/arztebl.2016.0597] [PMID: 27658473]
[70]
Mielke MM, Zandi PP, Sjögren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64(10): 1689-95.
[http://dx.doi.org/10.1212/01.WNL.0000161870.78572.A5 ] [PMID: 15911792]

Rights & Permissions Print Cite
Article Metrics
32
3
© 2024 Bentham Science Publishers | Privacy Policy